TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.
PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
PP405 is not a cure for hair loss but may reactivate dormant hair follicles, similar to minoxidil. It is unlikely to help with miniaturized or vellus hairs and is still in trial phases, with availability expected around 2030.
Minoxidil helps hair growth by increasing blood flow and prolonging the growthphase, but it doesn't address the root cause of hair loss, such as DHT sensitivity. Finasteride can help maintain some gains by blocking DHT, but stopping Minoxidil often leads to hair loss because the new hairs are dependent on it.
MCL-1 protein may help maintain hair follicles in the growthphase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.